Chemoimmunotherapy with fludarabine, cytoxan and rituximab regimen: To use, not to use, or give it as " FCR-LITE " ?

Leukemia and Lymphoma

Volumn 55, Issue 4, 2014, Pages 733-734

  Tadmor, Tamar ^a   McLaughlin, Peter ^b   Polliack, Aaron ^c  

^a BNAI ZION MEDICAL CENTER   (Israel)

^b UNIVERSITY OF TEXAS   (United States)

^c HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

BENDAMUSTINE; CYCLOPHOSPHAMIDE; FLUDARABINE; IBRUTINIB; LENALIDOMIDE; RITUXIMAB; ANTINEOPLASTIC AGENT;

BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CHRONIC LYMPHATIC LEUKEMIA; CYTOPENIA; DRUG EFFICACY; HUMAN; IMMUNE DEFICIENCY; INFECTION; LEUKEMIA REMISSION; MAINTENANCE THERAPY; NEUTROPENIA; NONHODGKIN LYMPHOMA; NOTE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SURVIVAL RATE; TREATMENT RESPONSE; FEMALE; LYMPHOMA, NON-HODGKIN; MALE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; LYMPHOMA, NON-HODGKIN; MALE;

EID: 84903218708     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2013.829575     Document Type: Note

References (18)

1. Boogaerts MA, Van HoofA, Catovsky D, et al. Activity of oral fludarabine phosphate in previously treated chronic lymphocytic leukemia. J Clin Oncol 2001;19:4252-4258. (Pubitemid 33081643)
2. Bollosillo B, Villamour N, Colomer D, et al. In vitro evaluation of fludarabine in combination with cyclophosphamide and/or mitoxantrone in B-cell chronic lymphocytic leukaemia. Blood 1999;94:2836-2843. (Pubitemid 29477312)
3. HochsterHS, OkenMM, Winter JN, et al. Phase I study offludarabine plus cyclophosphamide in patients with previously untreated low- grade lymphoma: results and long-term follow-up; a report from the Eastern Cooperative Oncology Group. J Clin Oncol 2000;18:987-994. (Pubitemid 30123774)
4. Catovsky D, Richards S, MatutesE, et al. Assessment offludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet 2007; 370: 230-239. (Pubitemid 47069536)
5. Wierda W, O'Brien S, Wen S, et al. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol 2005;23: 4070-4078. (Pubitemid 46211312)
6. Keating MJ, O'Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005; 23: 4079-4088. (Pubitemid 46211313)
7. Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial.Lancet 2010; 376: 1164-1174.
8. Zhou Y, Tang G, Medeiros LJ, et al. Therapy-related myeloid neoplasms following fludarabine, cyclophosphamide, and rituximab (FCR) treatment in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. Mod Pathol 2012; 25: 237-245.
9. Delgado J, Baumann T, Ghita G, et al. Chronic lymphocytic leukemia therapy: beyond chemoimmunotherapy. Curr Pharm Des 2012; 18: 3356-3362.
10. Marotta G, Bigazzi C, Lenoci M, et al. Low-dose fludarabine and cyclophosphamide in elderly patients with B-cell chronic lymphocytic leukemia refractory to conventional therapy.Haematologica 2000; 85: 1268-1270.
11. Fabbri A, Lenoci M, Gozzetti A, et al. Low-dose oral fludarabine plus cyclophosphamide in elderly patients with chronic lymphoproliferative disorders. Hematol J 2004; 5: 472-474. (Pubitemid 40045279)
12. Forconi F, Fabbri A, Lenoci M, et al. Low-dose oral fludarabine plus cyclophosphamide in elderly patients with untreated and relapsed or refractory chronic lymphocytic leukaemia. Hematol Oncol 2008; 26: 247-251.
13. Foon KA, Boyiadzis M, Land SR, et al. Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 2009; 27: 498-503.
14. Foon KA, Mehta D, Lentzsch S, et al. Long-term results of chemoimmunotherapy with low-dose fludarabine, cyclophosphamide and high-dose rituximab as initial treatment for patients with chronic lymphocytic leukemia. Blood 2012; 119: 3184-3185.
15. Fabbri A, CenciniE, RigacciL, et al. Efficayandsafetyofrituximab plus low-dose oral fludarabine and cyclophosphamide as first-line treatment of elderly patients with indolent non-Hodgkin lymphomas. Leuk Lymphoma 2014;55:781-785.
16. ChesonBD, Horning SJ, CoiffierB, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 1244-1253. (Pubitemid 29162950)
17. Wiestner A. Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 2012: 88-96.
18. Brown JR.Ibrutinib in chronic lymphocytic leukemia and B cell malignancies. Leuk Lymphoma 2013 Jun 24. [Epub ahead of print]